Santori & Peters, Inc. Ligand Pharmaceuticals Inc Transaction History
Santori & Peters, Inc.
- $251 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding LGND
# of Institutions
256Shares Held
18.1MCall Options Held
26.8KPut Options Held
9.3K-
Black Rock Inc. New York, NY2.87MShares$326 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.97MShares$223 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.01MShares$114 Million0.05% of portfolio
-
Macquarie Group LTD Australia, C3887KShares$101 Million0.1% of portfolio
-
State Street Corp Boston, MA707KShares$80.2 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.91B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...